Alvotech Consensus Price Target Increased by 10.13% to $7.40
The average one-year price target for Alvotech (NASDAQGM:ALVO) (DB:Z45) has been revised to $7.40 / share. This is an increase of 10.13% from the prior estimate of $6.71 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute a recommendation orinvestment adviceby Fintel. The price target is an average of many targets provided by analysts, with the latest individual targets ranging from a low of $4.04 to a high of $9.98 / share. The average price target represents an increase of 35.56% from the latest reported closing price of $5.46 / share on October 2, 2026.
Alvotech, based in Reykjavik, Iceland, is a prominent biopharmaceutical company specializing in the development and manufacture of biosimilar medicines. The company focuses on monoclonal antibodies and other protein-based biologics used in treating chronic diseases such as arthritis, psoriasis, and cancer. In its latest earnings report on August 19, 2026, Alvotech reported an actual EPS of -0.11, compared to an estimated EPS of -0.0275. The company's actual revenue was $105,906,000.00, which was below the estimated revenue of $113,169,000.00, representing a revenue surprise of -6.42%.
Looking at the company's target history, the mean target was $7.40 on October 2, 2026, following a mean target of $6.71 on September 16, 2026, $6.71 on August 29, 2026, and $6.63 on August 5, 2026. This represents a target change of +11.54% since the 90-day baseline date of June 30, 2026. Over a twelve-month period, the observed high mean target was $17.85 on November 9, 2025, while the observed low mean target was $6.63 on August 5, 2026. In terms of stock performance, Alvotech's price changed by -5.13% over one week from a baseline close of $5.75 on September 25, 2026, and changed by +2.15% over one month from a baseline close of $5.34 on September 2, 2026.
In recent rating actions, Barclays upgraded Alvotech from Underweight to Overweight on September 16, 2026. The company's recommendation trend for the period of September 1, 2026, shows 13 total recommendations, consisting of 4 strong buy, 6 buy, 2 hold, 1 sell, and 0 strong sell recommendations. This is an increase from the prior period of August 1, 2026, which had 11 total recommendations, including 3 strong buy, 5 buy, 2 hold, 1 sell, and 0 strong sell recommendations.
Within the broader market context, Alvotech is classified under the Financials sector, Capital Markets industry, and Asset Management & Custody Banks sub-industry. For this sub-industry, 32 companies are covered, with 7 experiencing raised targets, 9 lowered, and 16 unchanged. The sub-industry median revision percent is 0.00%, with a median implied change percent of +27.14%.
For comparison, several peer companies in the biosimilar and pharmaceutical markets show varying target revisions and implied changes. Among these peers, target revisions remained relatively flat or slightly positive, while implied changes varied widely.
| Company | Target revision | Implied change |
|---|---|---|
| Coherus Oncology | 0.00% | +512.88% |
| Amgen | +0.73% | -0.73% |
| Pfizer | +0.61% | +5.16% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.